The ACC’s Heart Failure and SGLT2is: The New Pillar in Care Initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) …

SGLT2 inhibitors were added to heart failure guidelines in 2022. Dapagliflozin and empagliflozin have shown benefits in patients with HFrEF, HFpEF, and HFmrEF with or without diabetes.7 SGLT2 …

Jun 3, 2025 · SGLT2 inhibitors have become an important class of medication in managing heart failure. Initially developed to treat diabetes, these drugs have shown clear benefits for patients with heart …

Mar 13, 2023 · Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent …

ABSTRACT Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-di-rected medical therapy in heart failure (HF) with reduced ejection fraction with recent trials …

Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve cardiovascular outcomes in patients who have heart failure with preserved ejection fraction (HFpEF)?

Apr 26, 2023 · Abstract The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits …

Jul 1, 2024 · Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently …

Jun 1, 2025 · Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are oral antidiabetic agents that have shown significant improvements in cardiovascular and renal outcomes among patients with …

Abstract Background Heart failure (HF) is a clinical diagnosis of a condition that develops secondary to either left ventricular systolic or diastolic functions. Lately, inhibitors of sodium-glucose cotransporter …